The FDA approved gedatolisib in PIK3CA wild-type breast cancer, granted full approval to selpercatinib in RET fusion+ tumors, and more.
|Videos|April 4, 2017
Dr. Janni on the Benefits of Targeted Therapies for HER2-Positive Breast Cancer
Author(s)Wolfgang Janni, MD, PhD
Wolfgang Janni, MD, PhD, University of Ulm, discusses the benefits of HER2-targeted therapies for patients with all stages of HER2-positive breast cancer.
Advertisement
Wolfgang Janni, MD, PhD, University of Ulm, discusses the benefits of HER2-targeted therapies for patients with all stages of HER2-positive breast cancer.
According to Janni, the benefits of HER2-targeted therapies in breast cancer outweigh the adverse events that patients experience.
The most common adverse events that are associated with HER2-targeted treatments include cardiotoxicity and diarrhea, states Janni.
Advertisement
Related to this article
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Catch up on insights into the global development of breast cancer treatments in the global spotlight.
Read our recap of top phase 1 and 2 breast cancer data highlights that may lead to further clinical research and developments.
Read our recap of the top phase 3 breast cancer data announcements and highlights that may make waves in the future of breast cancer management.
In case you missed any, check out our recap of the episodes of OncLive On Air that aired in June 2026.
Read a refresh of breast cancer FDA news from June 2026, including several practice-changing approvals and the granting of priority review to a SERD.
The FDA has approved zidesamtinib in patients with locally advanced/metastatic ROS1+ NSCLC who received a prior ROS1 kinase inhibitor.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Zidesamtinib in Pretreated ROS1+ NSCLC
2
NMPA Accepts Toripalimab Plus Chemotherapy Application for Expanded Stage II-III NSCLC Use
3
Ivonescimab Plus Chemotherapy Sustains OS Benefit Across Western and Asian Patients in Pretreated EGFR-Mutated NSCLC
4
Dr Patel on the Unmet Need in EGFR+ Transformed Small Cell Lung Cancer
5